Overview Request Sample Pages Request Customization Download PDF
You are viewing: Japan Drug Screening Market analysis
Part of: Drug Screening Market (Global)

The Japan Drug Screening Market was valued at $452.7 Million in 2025 and projected to reach to $987.6 Million by 2030, representing a compound annual growth rate of 16.9%. Japan's drug screening market is positioned for sustained growth through 2030, driven by intensifying workplace safety mandates and heightened substance abuse awareness across corporate and public sectors.

Japan Drug Screening Market Trends and Insights

  • Japan's market is driven by stringent workplace safety regulations, increasing substance abuse awareness, and advanced healthcare infrastructure that supports comprehensive screening programs.
  • The nation's aging population and emphasis on occupational health standards further accelerate demand for drug screening services across corporate, healthcare, and transportation sectors in Japan. The 16.9% compound annual growth rate in Japan reflects the country's commitment to preventive healthcare and regulatory compliance.
  • Japan's pharmaceutical and biotechnology sectors are investing heavily in innovative screening technologies, including rapid testing kits and laboratory automation.
  • Between 2025 and 2030, Japan is expected to see significant adoption of point-of-care testing solutions and digital integration in drug screening workflows, positioning the nation as a key market within the Asia Pacific region..

Key Market Statistics

  • CAGR (2025-2030) 16.9% CAGR
  • Market Size, 2025 ~USD 452.7 Million
  • Forecast, 2030 ~USD 987.6 Million
  • Country Japan

Japan Drug Screening Market Overview

Rapid Market Expansion :

Japan's drug screening market is projected to grow from $452.7 million in 2025 to $987.6 million by 2030, representing a robust 16.9% CAGR, outpacing the global average of 15.5%.

Stringent Regulatory Environment :

Japan's strict workplace safety regulations and mandatory drug screening requirements across industries drive consistent demand for comprehensive screening solutions and compliance-focused services.

Aging Population Impact :

Japan's demographic shift toward an aging society increases the need for drug screening in healthcare settings, long-term care facilities, and occupational health programs targeting senior workers.

Advanced Healthcare Infrastructure :

Japan's sophisticated healthcare system and high adoption of advanced screening technologies enable rapid integration of innovative testing methods and digital screening platforms.

Japan Drug Screening Market Dynamics

  • The nation's commitment to occupational health standards and regulatory compliance creates a stable foundation for market expansion.
  • Additionally, Japan's advanced healthcare infrastructure and technological capabilities support the adoption of cutting-edge screening methodologies.
  • The aging workforce demographic further amplifies demand for comprehensive screening programs in healthcare and occupational settings, ensuring continued market momentum..

Related Ecosystem

In Vitro Diagnostics

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Dna Microarrays
  • Assay Kits
  • Microarrays
Top Companies
  • ROCHE HOLDINGS AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Biomerieux s.a.

    Medical Devices

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Magnetic Resonance Imaging (MRI)
    • Disposable Autoinjectors
    • Pulse Oximeters
    • Blood Pressure Monitors
    Top Companies
    • Medtronic plc
    • Abbott Laboratories
    • Stryker Corporation
    • Becton, Dickinson and Company
    • JOHNSON & JOHNSON

      Key Takeaways

      • Japan's drug screening market will more than double from $452.7M (2025) to $987.6M (2030), representing a 16.9% CAGR.
      • Japan's stringent workplace safety regulations and occupational health standards drive consistent demand for screening services across multiple sectors.
      • Japan is adopting advanced technologies including rapid testing kits, laboratory automation, and point-of-care solutions to enhance screening efficiency.
      • Japan's aging population and emphasis on preventive healthcare position the nation as a high-growth market within Asia Pacific through 2030.

      Drug Screening Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment ON-SITE TESTING SERVICES (Type)
      Forecast Period 2025–2030
      Growth Rate CAGR of 15.5% from 2025 to 2030
      Largest Segment SERVICES (Offering)
      Market Size Base Year (Billions) ~USD 10.36 (2025)
      Revenue Forecast (Billions) ~USD 21.29 (2030)
      Segments Covered Offering, Type, Modality

      Japan Drug Screening Market Report Segmentation

      3 segment dimensions are covered across the global market.

      By Offering

      • Products
      • Services

      By Type

      • Analytical Instruments
      • Assay Kits
      • Breathalyzers
      • Calibrators & Controls
      • Chromatography Instruments
      • Consumables
      • Dip Cards
      • Drug Testing Cassettes
      • Drug Testing Cups
      • Fuel-Cell Breathalyzers
      • Immunoassay Analyzers
      • Laboratory Testing Services
      • On-Site Testing Services
      • Oral Fluid Testing Devices
      • Other Breathalyzers
      • Other Consumables
      • Rapid Testing Devices
      • Sample Collection Devices
      • Semiconductor Breathalyzers
      • Urine Testing Devices

      By Modality

      • Benchtop Breathalyzers
      • Handheld Breathalyzers

      Target Audience

      • Healthcare Providers & Hospitals : Need market data to expand drug screening services, understand demand drivers in Japan's healthcare sector, and align offerings with occupational health and patient safety requirements.
      • Corporate HR & Occupational Health Managers : Require insights on workplace screening regulations, compliance mandates, and market trends to implement effective employee drug testing programs and ensure workplace safety compliance.
      • Diagnostic & Testing Companies : Seek market intelligence on Japan's screening technology adoption, competitive landscape, and growth opportunities to develop localized products and expand market presence in this high-growth region.
      • Investment & Private Equity Firms : Need comprehensive market analysis, growth projections, and sector dynamics to evaluate investment opportunities in Japan's drug screening market and identify acquisition targets.
      • Government & Regulatory Bodies : Require market data to inform policy decisions, assess screening program effectiveness, and develop evidence-based occupational health and substance abuse prevention strategies for Japan.

      Key Companies in the Japan Drug Screening Market

      CompanyHQOwnershipStrongest segments
      UNILABSSwitzerlandPrivate CompanyLaboratory Testing (Core & Specialised),Medical Imaging,Pathology & Centres of Excellence,
      EIKEN CHEMICAL CO., LTD.JapanPublic CompanyFecal immunochemical test (FIT) reagents for colorectal cancer screening,Microbiological reagents and media (clinical),Urinalysis test strips,
      LABCORPUnited StatesPublic CompanyRoutine and specialty diagnostics (core lab, women’s health, chronic disease programs),Gene-based, esoteric, and advanced disease-targeted testing,Biopharma Laboratory Services (pharma, biotech, device, CRO clients),
      QUEST DIAGNOSTICS INCORPORATEDUnited StatesPublic CompanyRoutine and non-routine clinical testing,Advanced diagnostics and anatomic pathology,Life insurance risk assessment and workplace drug testing,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      ORASURE TECHNOLOGIES INC.United StatesPublic CompanyRapid infectious disease tests (HIV, HCV, syphilis, Ebola, COVID-19, SickleSCAN),Genomic saliva collection (Oragene, ORAcollect),Microbiome collection (OMNIgene GUT, SALIVA, Dx),
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
      DRäGERWERK AG & CO. KGAAGermanyPublic CompanyAcute-care capital equipment (ventilators, anaesthesia, monitoring, lights, pendants),Neonatal care and perinatal systems,Medical infrastructure, gas pipeline systems, and hospital planning,
      LIFELOC TECHNOLOGIES, INC.United StatesPublic CompanyHand-held fuel-cell breathalyzers (professional),Fixed and zero-tolerance screening stations (Sentinel, R.A.D.A.R.),Calibration systems, supplies, and accessories (EASYCAL, consumables),
      MPD INC.AustraliaPrivate CompanyLiquid milk & cream,Cheese (block, shredded, specialty),Butter, spreads & fats,
      PSYCHEMEDICS CORPORATIONUnited StatesPublic CompanyEmployer job applicant and employee hair drug testing,Law enforcement and court-mandated testing,Schools and educational institutions,
      SHIMADZU CORPORATIONJapanPublic CompanyAnalytical and Measuring Instruments,Medical Systems,Vacuum and Industrial Machinery,
      SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging,Diagnostics,Varian (Oncology),

      UNILABS

      UNILABS is a Swiss private laboratory services company established in 1987 with 1,897 employees.

      EIKEN CHEMICAL CO., LTD.

      Eiken Chemical Co., Ltd. is a Japanese public company founded in 1939 with 696 employees engaged in chemical manufacturing.

      LABCORP

      LabCorp is a United States-based public clinical laboratory company founded in 1995 with 66,385 employees providing diagnostic testing services.

      QUEST DIAGNOSTICS INCORPORATED

      Quest Diagnostics Incorporated is a publicly traded American diagnostic testing company established in 1967 with 51,500 employees.

      ABBOTT

      Abbott is a multinational American public company founded in 1888 with 115,000 employees operating in healthcare and diagnostics.

      ORASURE TECHNOLOGIES INC.

      OraSure Technologies Inc. is a United States public company founded in 1987 with 500 employees specializing in diagnostic testing products.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a large American public company founded in 1956 with 125,000 employees providing scientific and laboratory services.

      DRäGERWERK AG & CO. KGAA

      Drägerwerk AG & Co. KGaA is a German public company founded in 1889 with 16,033 employees specializing in medical and safety technology.

      LIFELOC TECHNOLOGIES, INC.

      LifeLoc Technologies, Inc. is a United States public company founded in 1983 with 37 employees.

      MPD INC.

      MPD Inc. is an Australian private company founded in 1977 with 40 employees.

      PSYCHEMEDICS CORPORATION

      PsycheMedics Corporation is a publicly traded American company founded in 1986 with 101 employees.

      SHIMADZU CORPORATION

      Shimadzu Corporation is a Japanese public company founded in 1875 with 14,649 employees manufacturing analytical and scientific instruments.

      SIEMENS HEALTHINEERS AG

      Siemens Healthineers AG is a German public healthcare technology company founded in 1896 with 72,369 employees.

      Reasons to Buy this Report

      • Market Size & Growth Validation : Confirm Japan's drug screening market valuation at $452.7M (2025) and $987.6M (2030) with detailed CAGR analysis to support investment decisions and business planning in this high-growth market.
      • Regulatory Compliance Insights : Understand Japan's stringent workplace safety regulations and mandatory screening requirements to develop compliant products and services tailored to local regulatory frameworks and industry standards.
      • Competitive Positioning Strategy : Identify market dynamics, competitive landscape, and growth drivers specific to Japan to benchmark performance, identify white space opportunities, and refine go-to-market strategies for Japanese stakeholders.
      • Demographic & Sector Opportunities : Leverage insights on Japan's aging population and occupational health emphasis to target high-demand segments including healthcare facilities, long-term care, and corporate wellness programs.
      • Technology Adoption Trends : Access data on Japan's advanced healthcare infrastructure and technology adoption rates to identify opportunities for innovative screening solutions and digital platform integration in the market.

      Frequently asked questions

      What is the current size of Japan's drug screening market?

      Japan's drug screening market is valued at $452.7 million in 2025 and is projected to reach $987.6 million by 2030.

      What is the growth rate of Japan's drug screening market?

      Japan's drug screening market is growing at a compound annual growth rate (CAGR) of 16.9% from 2025 to 2030.

      What factors are driving growth in Japan's drug screening market?

      Growth in Japan is driven by stringent workplace safety regulations, increasing substance abuse awareness, advanced healthcare infrastructure, and an aging population requiring preventive health measures.

      Which sectors in Japan are adopting drug screening services?

      Japan's drug screening services are widely adopted across corporate, healthcare, transportation, and occupational health sectors due to regulatory compliance requirements.

      What technologies are being adopted in Japan's drug screening market?

      Japan is increasingly adopting rapid testing kits, laboratory automation, point-of-care testing solutions, and digital integration in drug screening workflows between 2025 and 2030.

      RESEARCH METHODOLOGY

      The study involved five major activities to estimate the current size of the drug screening market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.

      Secondary Research

      In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for the study of the drug screening market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.

      Primary Research

      Extensive primary research was conducted after acquiring basic knowledge about the global drug screening market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (Hospital directors, Hospital Vice Presidents, Department heads, and Critical care specialists ) and supply side (such as C-level and D-level executives, technology experts, product managers, marketing and sales managers, among others) across five major regions North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

      The following is a breakdown of the primary respondents:

      BREAKDOWN OF PRIMARY PARTICIPANTS:

      Drug Screening Market Size, and Share

      Note 1: Others include sales managers, marketing managers, and product managers.
      Note 2: Tiers of companies are defined on the basis of their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total size of the drug screening market. These methods were also used extensively to estimate the size of various subsegments in the market.

       The research methodology used to estimate the market size includes the following:

      Drug Screening Market Top Down and Bottom Up Approach

      Data Triangulation

      After arriving at the overall market size using the market size estimation processes, the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the drug screening market.

      Market Definition

      Drug and alcohol testing or drug screening refers to testing individuals for illegal abuse of drugs (including legal drugs such as prescription drugs) through the use of biological samples, such as urine, oral fluids/saliva, hair, blood, and sweat.

      Key Stakeholders

      • Drug screening product & solution providers (Including immunoassay kit manufacturers, confirmatory testing technology providers, breathalyzer and oral fluid testing device developers, rapid test and POCT vendors)
      • Drug screening service providers (including Clinical laboratories, reference labs, forensic toxicology labs, workplace testing providers, on-site/mobile testing service companies)
      • Healthcare providers (Hospitals, emergency departments, trauma centers, outpatient clinics, rehabilitation centers, pain management clinics, mental health and addiction treatment facilities)
      • Workplace & employer organizations
      • Law enforcement & public safety agencies
      • Research & development (R&D) companies
      • Judicial & legal system stakeholders
      • Government & regulatory authorities
      • Sports organizations & anti-doping agencies
      • Payers & insurers
      • Patients, employees & tested individuals
      • Substance abuse treatment & rehabilitation providers
      • Research & development (R&D) organizations
      • Venture capitalists & private equity firms
      • Advocacy groups & professional associations
      • Investors & financial institutions
      • Medical research laboratories & clinical trial organizations
      • Academic institutions & training centers   
      • Technology & instrumentation providers
      • Laboratory information & data management providers
      • Sample collection & logistics providers
      • Quality assurance, accreditation & certification bodies
      • Consulting, training & compliance service provider
      • Data analytics & emerging technology developers

      Report Objectives

      • To define, describe, and forecast the global drug screening market based on offering, sample type, drug type, end user, and region
      • To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
      • To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall drug screening market
      • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To strategically analyze the market structure profile of the key players of the drug screening market and comprehensively analyze their core competencies
      • To forecast the size of the market segments with respect to five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
      • To track and analyze competitive developments such as product launches and enhancements, investments, partnerships, collaborations, acquisitions, expansions, product approval, and alliances in the drug screening market during the forecast period.

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
      • Product Analysis: Product matrix, which gives a detailed comparison of the product portfolios of each company.
      • Geographic Analysis:  Further breakdown of Latin America, Europe,  and the Middle East & Africa drug screening into specific countries

       

      Get the Full Drug Screening Market Report

      Full forecast, segment splits, and company analysis for all Drug Screening Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status